A series of studies showed that the genotype of a genomic variant rs9679162, located on the Polypeptide N-Acetylgalactosaminyltransferase 14 (GALNT14) gene, was consistently associated with the treatment outcome of intermediate and advanced HCC [24,25,26,27,28,29]. This evidence concerns the gene GALNT14 and hepatocellular carcinoma.